Home > Boards > US Listed > Medical - Drugs > Allergan (AGN)

Adverse ruling on Restasis patent in US District Court:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 722
Posts 109,328
Boards Moderated 13
Alias Born 09/05/02
160x600 placeholder
Allergan to Report Third Quarter 2019 Financial Results PR Newswire (US) - 10/17/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2019 6:35:12 AM
Allergan Shareholders Approve Proposed Acquisition by AbbVie PR Newswire (US) - 10/14/2019 9:15:00 AM
Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascu... PR Newswire (US) - 10/11/2019 7:40:00 PM
On World Sight Day, Allergan Launches National Campaign to Raise Awareness of the Toll Glaucoma Takes on Everyday Living PR Newswire (US) - 10/10/2019 7:30:00 AM
Allergan Expands REFRESH® Portfolio With New REFRESH® RELIEVA™ Lubricant Eye Drop Product Line PR Newswire (US) - 10/7/2019 7:30:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/3/2019 4:11:56 PM
Allergan to Showcase Late-Stage Data in Age-Related Macular Degeneration and Glaucoma at American Academy of Ophthalmology An... PR Newswire (US) - 10/3/2019 7:30:00 AM
Drugmakers Look to Use Purdue Pharma's Bankruptcy to Settle Opioid Suits Dow Jones News - 9/30/2019 5:41:00 PM
FTC Requests for More Information From AbbVie-Allergan Tie-Up Dow Jones News - 9/27/2019 5:38:00 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 9/27/2019 4:51:03 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2019 4:46:54 PM
Allergan and AbbVie Receive Second Request from Federal Trade Commission on Pending Transaction PR Newswire (US) - 9/27/2019 4:16:00 PM
AbbVie and Allergan Receive Second Request from Federal Trade Commission on Pending Transaction PR Newswire (US) - 9/27/2019 4:15:00 PM
Announcement under the Irish Takeover Rules: Relevant Securities in Issue - September 17, 2019 PR Newswire (US) - 9/17/2019 4:15:00 PM
Allergan Announces Commencement of Mailing of Proxy Statement PR Newswire (US) - 9/17/2019 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/16/2019 4:17:54 PM
Proxy Statement - Merger or Acquistion (definitive) (defm14a) Edgar (US Regulatory) - 9/16/2019 4:02:54 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/11/2019 6:36:11 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 9/11/2019 6:35:28 AM
Allergan Shareholder Meetings Scheduled for October 14, 2019 PR Newswire (US) - 9/10/2019 4:36:00 PM
Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing... PR Newswire (US) - 9/9/2019 7:30:00 AM
Allergan Receives FDA Approval of Juvéderm VOLUMA® XC For Mid-Face Injection Via Cannula PR Newswire (US) - 9/3/2019 7:30:00 AM
Allergan Announces Settlement with Two Ohio Plaintiffs in Federal Opioid Litigation PR Newswire (US) - 8/30/2019 7:00:00 AM
Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rit... PR Newswire (US) - 8/22/2019 9:00:00 AM
DewDiligence Member Level  Monday, 10/16/17 02:04:54 PM
Re: DewDiligence post# 137
Post # of 195 
Adverse ruling on Restasis patent in US District Court:

https://finance.yahoo.com/news/u-district-court-eastern-district-174500864.html
Quote:
Allergan plc…today acknowledged that the U.S. District Court for the Eastern District of Texas has issued an adverse trial decision finding that the four asserted patents covering RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05% are invalid. The Company will appeal the Court's ruling.

…The patents include United States Patent Nos. 8,629,111; 8,648,048; 8,685,930 and 9,248,191. These patents, along with United States Patent Nos. 8,633,162 and 8,642,556, are listed in the Orange Book for RESTASIS and expire on August 27, 2024.

Unless overturned on appeal, the Districtt Court’s ruling blows up AGN’s patent settlement with PFE (#msg-135360904).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist